Mercado mundial de tratamiento de la osteoartritis: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado

En los últimos años, se prevé que el mercado de tratamiento de la osteoartritis crezca rápidamente durante el período de pronóstico. Según la Organización Mundial de la Salud, entre el 10% y el 15% de todas las personas mayores de 60 años padecen osteoartritis, siendo las mujeres las que presentan una prevalencia mayor que los hombres. Según las Naciones Unidas, los adultos mayores de 60 años representarán más del 20% de la población mundial en 2050. Una estimación conservadora de que el 15% de este 20% tendrá osteoartritis sintomática, y un tercio de este grupo la padecerá gravemente.

Data Bridge Market Research analiza que el mercado de tratamiento de la osteoartritis se valoró en USD 6.214,06 millones en 2021 y se espera que alcance los USD 10.100,30 millones para 2029, registrando una CAGR del 6,26% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Market Definition

The most prevalent chronic disease affecting the joints is osteoarthritis, often known as degenerative arthritis. The affected body parts experience acute joint pain and stiffness as a result of this. Osteoarthritis can be treated with a variety of methods, including exercise for joint pain relief and pain medicines. OA symptoms can be relieved with over-the-counter (OTC) pain medications such as acetaminophen (Tylenol) or a nonsteroidal anti-inflammatory drug (NSAID). Duloxetine (Cymbalta) is a prescription pain reliever that can also be used to treat long-term (chronic) OA discomfort. Steroid injections can often provide significant relief from OA pain in the short to medium term.

Osteoarthritis Treatment Market Dynamics

Drivers

• Increasing prevalence of osteoarthritis

The rising prevalence of osteoarthritis is estimated to enhance the osteoarthritis treatment market's growth. Injury, obesity, and a variety of other factors contribute to osteoarthritis. The damaged bodily part has severe joint pain and stiffness. Swelling of joints, tingling in the legs and limbs, and a reduction in range of motion are all indications of osteoarthritis. As per a study published in the Lancet Journal in November 2020, osteoarthritis affected about 7% of the global population, or more than 500 million people, in 2019, with women disproportionately affected. The number of people affected by osteoarthritis globally increased by 48 percent from 1990 to 2019, and osteoarthritis was the 15th leading cause of years lived with disability (YLDs) in 2019.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of osteoarthritis treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to getting osteoarthritis treatment, further estimated to enhance theirmarket's growth rate.

• Surging cases of joint injuries

The increasing number of joint injuries is estimated to elevate the 'market's growth rate. Osteoarthritis can be worsened by injuries sustained while participating in sports or as a result of an accident. Osteoarthritis can be triggered by injuries that occurred many years ago but appear to have healed.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the osteoarthritis treatment market. Additionally, rising incidences of orthopedic disorders and sedentary lifestyle of people will expand the osteoarthritis treatment market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities of medication for symptomatic treatment of osteoarthritis. This will provide beneficial opportunities for the osteoarthritis treatment market growth. For illustration, Flexion Therapeutics, Inc. began a Phase III investigation of FX006 32 mg, which is indicated for knee osteoarthritis, in April 2018.

Moreover, rising investment in the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the osteoarthritis treatment market growth during the forecast period.

Restraints/Challenges

• Side effects linked with Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

NSAIDs, both over-the-counter and prescribed, are commonly used to treat osteoarthritis pain. According to a report published by the National Center for Biotechnology Information in 2019, NSAIDs are administered to more than half of all osteoarthritis patients in the United States. Similarly, 60 percent of osteoarthritis patients in Europe who used prescription drugs (47 percent) received NSAIDs. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been linked to an enhanced risk of cardiovascular events. Both selective and non-selective NSAIDs (coxibs) increase the risk of cardiovascular disease in patients. These factors will impede the 'market's growth rate during the forecast period of 2021-2029.

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the osteoarthritis treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This osteoarthritis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteoarthritis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

X-rays reveal osteoarthritis in about 80% of elderly persons aged 55 and more. Approximately 60% of these people suffer from symptoms. Symptomatic osteoarthritis affects an estimated 240 million adults globally, including over 30 million adults in the United States. Knee osteoarthritis occurs more frequently in postmenopausal women than in males.

Osteoarthritis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Osteoarthritis Treatment Market

Durante el período proyectado, se esperaba que el mercado de tratamiento de la osteoartritis se viera limitado por el brote de COVID-19. Desde su aparición en diciembre de 2019, el virus COVID-19 se ha propagado a casi todos los países del planeta, lo que llevó a la Organización Mundial de la Salud (OMS) a declararlo una emergencia de salud pública. COVID-19, un nuevo coronavirus, fue identificado como el agente causal de los casos de neumonía. Este virus se propagó rápidamente por todo el mundo, matando a muchas personas. La Organización Mundial de la Salud (OMS) etiquetó al COVID-19 como una pandemia mundial en marzo de 2020, y se recomendaron medidas rigurosas para prevenir la propagación de la enfermedad. Desde entonces, la pandemia ha retrasado la expansión del sector de la salud y ha interrumpido la cadena de suministro. Además, los gobiernos de muchas naciones habían impuesto cierres a nivel nacional para detener la propagación de COVID-19. De manera similar, las organizaciones de atención médica en numerosas naciones de todo el mundo estaban teniendo dificultades para continuar con sus actividades de la cadena de suministro. El mercado de tratamiento de la osteoartritis se vio obstaculizado por la lentitud de la cadena de suministro.

Desarrollo reciente

• En diciembre de 2020, Moebius Medical anunció la autorización de la Administración de Alimentos y Medicamentos de los EE. UU. (FDA) para su solicitud de nuevo fármaco en investigación (IND) para iniciar un ensayo clínico global multicéntrico de fase IIb de MM-II, que es un nuevo candidato para el tratamiento del dolor debido a la osteoartritis de rodilla (OA).

Alcance del mercado mundial de tratamiento de la osteoartritis

El mercado de tratamiento de la osteoartritis está segmentado en función de la anatomía, el tipo de fármaco, el tipo de tratamiento, el diagnóstico, la forma de dosificación, la vía de administración, los usuarios finales y el canal de distribución. El crecimiento entre estos segmentos le ayudará a analizar los escasos segmentos de crecimiento de las industrias y brindará a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.

Anatomía

• Osteoartritis de la mano
• Osteoartritis de rodilla
• Osteoartritis de cadera
• Osteoartritis de articulaciones pequeñas

Tipo de droga

• Medicamentos con receta
• Medicamentos de venta libre

Tipo de tratamiento

• Medicamento
• Duloxetina
• Paracetamol
• Medicamentos antiinflamatorios no esteroides (AINE)
• Corticosteroides
• Otros
• Cirugía
• Reemplazo de articulación
• Realineación de los huesos
• Inyecciones de lubricación
• Inyecciones de cortisona
• Terapia
• Estimulación nerviosa eléctrica transcutánea (TENS)
• Terapia ocupacional
• Fisioterapia

Diagnóstico

• Pruebas de imagen
• Imágenes por resonancia magnética (IRM)
• Rayos X
• Análisis del líquido articular
• Análisis de sangre
• Otros

Forma de dosificación

• Tabletas
• Inyecciones
• Otros

Vía de administración

• Oral
• Parenteral
• Otros

Usuarios finales

• Hospitales
• Clínicas de especialidades
• Cuidado domiciliario
• Otros

Canal de distribución

• Farmacia hospitalaria
• Farmacia minorista
• Farmacia en línea
• Otros

Análisis y perspectivas regionales del mercado de tratamiento de la osteoartritis

Se analiza el mercado de tratamiento de la osteoartritis y se proporcionan información y tendencias del tamaño del mercado por país, anatomía, tipo de fármaco, tipo de tratamiento, diagnóstico, forma de dosificación, vía de administración, usuarios finales y canal de distribución como se mencionó anteriormente.

The countries covered in the osteoarthritis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the osteoarthritis treatment market because of the launch of new treatment options in this region. Additionally, rising healthcare expenditure along with the availability of treatment options will further propel the 'market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to presence of generic manufacturers in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the 'market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Osteoarthritis Treatment Market Share Analysis

The Osteoarthritis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteoarthritis treatment market.

Some of the major players operating in the osteoarthritis treatment market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France), Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Zydus Cadila (India)
• Boehringer Ingelheim International GmbH. (Germany)
• Apotex Inc. (Canada)
• AstraZeneca (U.K.)
• Horizon Therapeutics PLC (Ireland)
• Johnson & Johnson Private Limited (U.S.)
• Bayer AG (Germany)
• Perrigo Company plc (Ireland)
• Tolmar Pharmaceuticals, Inc. (U.S.)
• Reckitt Benckiser Group PLC (U.K.)
• Industrias farmacéuticas Sun Ltd. (India)
• Assertio Therapeutics, Inc. (EE. UU.)
• DAIICHI SANKYO COMPANY, LIMITED (Japón)

SKU-53320